Sign In
Buy PACB
$1.15
-0.0350 (-2.95%)
At Close: Aug 10, 2026
Here's Why You Should Add PacBio Stock to Your Portfolio Now
01:11pm, Wednesday, 01'st Apr 2026
PACB's strong Q4 results, expanding sequencing tech portfolio and rising system adoption highlight growth momentum despite ongoing purchasing cycle challenges.
Pacific Biosciences of California (PACB) Registers a Bigger Fall Than the Market: Important Facts to Note
07:15pm, Friday, 27'th Mar 2026
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.26, representing a -6.67% change from its previous close.
PacBio Wins Basecamp Research Deal for Trillion Gene Atlas Initiative
10:06am, Thursday, 26'th Mar 2026
PACB wins Basecamp deal to power Trillion Gene Atlas using HiFi sequencing, advancing AI-driven drug discovery with high-accuracy genomic data.
Pacific Biosciences (PACB) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:00pm, Wednesday, 18'th Mar 2026
Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative
09:05am, Wednesday, 18'th Mar 2026
PacBio's Revio system and SPRQ-Nx chemistry to enable an order-of-magnitude expansion of HiFi metagenomic sequencing for scaling AI-designed therapeutics PacBio's Revio system and SPRQ-Nx chemistry to
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
08:30am, Thursday, 05'th Mar 2026
Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencing Proven experience in leveraging AI in biolog
Head to Head Survey: Pacific Biosciences of California (NASDAQ:PACB) and NexGel (NASDAQ:NXGL)
01:10am, Thursday, 05'th Mar 2026
Pacific Biosciences of California (NASDAQ: PACB - Get Free Report) and NexGel (NASDAQ: NXGL - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contr
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub
11:15am, Tuesday, 03'rd Mar 2026
PACB teams with DNAstack to launch a global HiFi genome network, linking 10,000+ sequences to boost rare disease research without moving data.
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
09:05am, Tuesday, 24'th Feb 2026
Collaboration powers secure international data sharing through the HiFi Solves Global Consortium Collaboration powers secure international data sharing through the HiFi Solves Global Consortium
Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $524,232.94 in Stock
04:32am, Sunday, 22'nd Feb 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) insider Christian Henry sold 331,793 shares of the firm's stock in a transaction on Tuesday, February 17th. The stock was sold
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
11:51am, Friday, 20'th Feb 2026
Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.
PacBio to Participate in the TD Cowen 46th Annual Health Care Conference
04:05pm, Wednesday, 18'th Feb 2026
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate
Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
07:27am, Saturday, 14'th Feb 2026
Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up
11:25am, Friday, 13'th Feb 2026
PACB beats Q4 estimates as revenue jumps 14%, gross margin hits 41% and 2026 revenues are projected in the range of $165-$180M after strategic moves.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
06:35pm, Thursday, 12'th Feb 2026
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.2 per share a year ago.
